hello Paul - probably you are right, for you are using its corporate history to extrapolate its future. What I want to say is what is the ideal case, especially now it has a semi-clean slate.
If and when it comes out with some promising clinical data, especially Ragweed Allervax from a Phase III, it is almost there. So, even if it has to go to the equity mkt, my guess is that there is no shortage of demand.
However, I also agree with you that it may or may have enough capital capital to burn. While I think it was spoiled in the past because the former mgt didn't recognize the sugar daddy would cut the loss and leave and I think sometimes it is excellent incentive for people to know that their research work is not mere flight of fancy, it is important to strike a balance between too much and too little. I don't ve inside information about IMUL per se, but many biotech cos are so broken that their labs are empty and the still-employed are lo in morale. If the new CEO is a capable person, he should know that and seek remedy - and the best remedy, outside of the bureaucratic choke hold of FDA, is to have the reassurance of a corporate sponsor. So, I guess, this is a wishlist, not necessary reality.
rgds Bosco |
